OneVentures

OneVentures is one of Australia’s largest later-stage venture firms, operating from Sydney with a thesis focused on transformative medical devices, biotech, and pharmaceutical therapeutics companies pursuing globally scalable opportunities. The firm runs both venture equity and venture credit strategies, which is unusual in the ANZ market and gives it the capital flexibility to support companies through the long capital-intensive arcs that medical device and biotech development typically require.

The healthcare thesis at OneVentures emphasizes companies with substantial scientific or engineering differentiation, credible regulatory pathways, and global commercial potential. The portfolio includes BiVACOR, a total artificial heart company representing the kind of long-horizon medical device investment the firm is willing to underwrite. The team uses milestone-based tranching as a discipline, structuring investments around clinical and regulatory inflections rather than fixed time periods, which aligns capital deployment with actual technical progress in companies where development is inherently nonlinear.

Check sizes commonly fall in the five to twenty-five million dollar range, with the firm participating at Series A, Series B, and growth rounds. The later-stage focus distinguishes OneVentures from peers concentrated at seed and Series A, and it positions the firm as a useful partner for ANZ medical device and biotech companies that have moved past initial science risk and need substantial capital to advance through clinical development and commercial scale-up. Geographic focus is Australia and New Zealand with active engagement in companies that have international clinical trials, manufacturing, or commercial operations.

The team includes senior partners with backgrounds in venture, life sciences, and operating roles at medical device and pharmaceutical companies, supported by both equity and credit investment staff. Diligence is rigorous on regulatory pathway, clinical evidence, and capital efficiency, and the firm’s milestone tranching approach reflects a serious discipline rather than a marketing posture. Decision-making is structured but not slow for prepared founders.

For founders, OneVentures is most useful when the company has crossed the early science risk threshold and needs a substantial later-stage capital partner with credibility in regulatory and commercial development. Useful introductions tend to involve clinical advisors and key opinion leaders, regulatory specialists in major markets, contract manufacturers for medical device and pharmaceutical scale-up, and downstream strategic acquirers in the device and pharma industries. Post-investment engagement is active at board level and on milestone tracking, given the tranched capital structure that requires close coordination between management and the firm. Founders unwilling to operate against a structured milestone framework will find the firm’s discipline restrictive, but for medical device and biotech founders who actively want a sophisticated later-stage partner with real understanding of capital intensive healthcare development, OneVentures is among the most credible options in the ANZ market and one of the few firms that can credibly carry a company from Series A through commercial readiness.